Toronto, Ontario – July 29, 2016, Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that it has filed an Investigational Testing Authorization (“ITA”) with Health Canada for approval to use its patent pending TLC-3200 Photo Dynamic Therapy (“PDT”) Laser System and TLC-34XX Dosimetry Fibre Optic Cage (“DFOC”) technology, in conjunction with its Clinical Trial Application (“CTA”) approved lead PDC, TLD-1433, in a Phase Ib clinical trial for the treatment of Non-Muscle Invasive Bladder Cancer (“NMIBC”).   The TLC-3200 PDT Laser System delivers green laser light, at a wavelength of 525 nanometers (“nm”), while the DFOC technology precisely monitors the laser light to provide a uniform distribution of the laser light energy, in the correct dosage, to the bladder wall.   The clinical … Read More

Toronto, Ontario – June 22, 2016, Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that it has filed a US patent for its proprietary Dosimetry Fibre Optic Cage (“DFOC”) technology. DFOC technology allows Theralase to precisely monitor and remotely control laser light energy delivered to hollow organs, such as the bladder, when undergoing treatment with Theralase’s lead anti-cancer drug, TLD-1433, currently under investigation for the destruction of Non-Muscle Invasive Bladder Cancer (“NMIBC”). The patent application is entitled, “Fiber Optic-Based Photodynamic Treatment Delivery and Irradiance Monitoring System and has been licenced to Theralase under a royalty agreement with Princess Margaret Cancer Centre, University Health Network (“UHN”).” The current methodology planned for the Phase Ib clinical study for NMIBC involves: ? Intravesical installation of … Read More

Toronto, Ontario – June 20, 2016, Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that it has been granted a US patent for its lead anti-cancer drug, TLD-1433, by the United States Patent and Trademark Office (“USPTO”). US patent number 9,345,769 (filed on April 15, 2013 and issued on May 24, 2016) provides patent protection for tens of thousands of metal based PDCs; including, Theralase’s lead anti-cancer drug, TLD-1433, currently under investigation by the Company for the destruction of Non-Muscle Invasive Bladder Cancer (“NMIBC”). The US patent provides patent protection for Theralase’s second major platform of anti-cancer PDCs for twenty years from date of filing, plus an allowable extension of 433 days, providing a minimum patent protection in the US of TLD-1433 … Read More

Toronto, Ontario – June 20, 2016, Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that it has been granted a US patent for its lead anti-cancer drug, TLD-1433, by the United States Patent and Trademark Office (“USPTO”).   US patent number 9,345,769 (filed on April 15, 2013 and issued on May 24, 2016) provides patent protection for tens of thousands of metal based PDCs; including, Theralase’s lead anti-cancer drug, TLD-1433, currently under investigation by the Company for the destruction of Non-Muscle Invasive Bladder Cancer (“NMIBC”).   The US patent provides patent protection for Theralase’s second major platform of anti-cancer PDCs for twenty years from date of filing, plus an allowable extension of 433 days, providing a minimum patent protection in the US … Read More

Toronto, Ontario – May 12, 2016, Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that it has signed a Clinical Research Agreement (“CRA”) with Princess Margaret Cancer Centre, University Health Network (“UHN”) to conduct a Phase Ib clinical study for the indication of Non-Muscle Invasive Bladder Cancer (“NMIBC”). The clinical study entitled, “A Phase Ib Trial of Intravesical Photodynamic Therapy in Patients with Non-Muscle Invasive Bladder Cancer at High Risk of Progression Who Are Refractory to Therapy with Bacillus Calmette-Guerin (“BCG”) and Who Are Medically Unfit for or Refuse a Cystectomy”, will be conducted by the Department of Urology at UHN, under the guidance of clinical principal investigator, Dr. Girish Kulkarni. Dr. Girish Kulkarni, uro-oncologist at UHN stated, “I have worked closely … Read More

Toronto, Ontario – May 11, 2016, Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that it presented its latest anti-cancer technology research at the 111th Annual American Urological Association (“AUA”) Meeting and Exposition in San Diego, California.   Dr. Lothar Lilge, Senior Scientist at Princess Margaret Cancer Centre, University Health Network, (“UHN”) in Toronto and lead author presented Theralase’s latest pre-clinical research in the treatment of Non-Muscle Invasive Bladder Cancer (“NMIBC”).   The AUA Annual Meeting is the largest gathering of urologists in the world and provides unparalleled access to ground breaking research, new guidelines and the latest advances in urologic medicine. Founded in 1902, the AUA is a premier urologic association, providing invaluable support to the urologic community with a mission … Read More

Toronto, Ontario – April 29, 2016, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotech company focused on commercializing medical devices to eliminate pain and developing Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that it has increased its revenues by 40% year over year in its latest audited 2015 financial statements.   Total revenue for the year ended December 31, 2015 increased 40% from $1,380,604 to $1,945,246 from the same period in 2014.   In Canada, revenue increased 97% to $1,691,086 from $857,723, while US revenue decreased 24% from $283,784 to $214,744 and international revenue decreased 84% from $239,097 to $39,415.   The significant increase in Canadian revenue in 2015 and the corresponding decrease in US and international revenue is directly attributable to the Company’s mandate of building its sales and marketing teams from scratch commencing with the Canadian market. The next generation TLC-2000 therapeutic … Read More

Toronto, Ontario – April 22, 2016, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotech company focused on commercialization of medical devices to eliminate pain and development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that it has reached a milestone, demonstrating 6 month accelerated stability and 9 month long term stability of it lead anti-cancer PDC, TLD-1433. Stability studies are an essential component of pharmaceutical development, allowing evaluation of a drug’s stability under the influence of a variety of environmental factors such as: temperature, humidity and light. Data from these studies enable recommended storage conditions, retest intervals and shelf lives to be established. Demonstrating accelerated and long term stability of a drug to be used in human clinical testing is essential to prove that the potency and/or efficacy of the drug is not affected during prolonged shelf life. Under accelerated and long term stability … Read More

Toronto, Ontario – April 15, 2016, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that the latest research on combining its lead Photo Dynamic Compound (“PDC”), TLD-1433, with transferrin, to enhance the ability of TLD-1433 to target cancer cells, was recently published in a leading peer reviewed international journal related to Photo Dynamic Therapy (“PDT”).   Transferrin is a glycoprotein that naturally occurs in the body and is used to transport iron to cells. Theralase has been investigating the use of transferrin to decrease the toxicity, improve the selectivity and increase the efficacy of its lead compound TLD-1433 in the destruction of cancer cells.   The new publication, entitled, “Ruthenium(II) based Photosensitizer and Transferrin Complexes Enhance Photo-physical Properties, Cell Uptake, and Photodynamic Therapy Safety and Efficacy” was published in Photochemical & Photobiological … Read More

Toronto, Ontario – March 18, 2016, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today an update on the 2016 strategic initiatives of the Company.   The Company has two primary divisions, the Therapeutic Laser Technology (“TLT”) division and the Anti-Cancer Photo Dynamic Therapy (“PDT”) division.   The TLT division is focused on increasing revenues of its next generation TLC-2000 therapeutic laser system in Canada and the US in 2016. Health Canada and the US Food and Drug Administration approved the TLC-2000 for commercial distribution in December 2015. The Company will report revenue generated from the TLT division in fiscal year 2015 on April 29, 2016 and revenue generated in the 1st quarter 2016 on May 30, 2016. Subsequent quarters are expected to show a steady increase in revenue for the TLT division, … Read More